• 5-May-2011: MNTA reports 1Q11 financial results. We already know that NVS booked $247M of 1Q11 Lovenox sales, implying at least $70M of Lovenox profit for MNTA.
• 4-Feb-2013: Start of NVS/MNTA’s patent-infringement suit against Teva. (Please see #msg-61591240 for the relevance of this.)
Copaxone
• Timing uncertain: FDA feedback on Copaxone ANDA. MNTA would presumably disclose these details only if they were deemed to have a material affect on the probability or timing of FDA approval.
• Timing uncertain: District Court ruling on Markman hearing. This may provide early feedback on the likely outcome of the Copaxone patent trial with respect to Teva’s Orange-Book and process patents; however, it is not assured that the Judge will rule on the Markman hearing prior to the trial.
• 7-Sep-2011: Start of trial on validity/enforceability of Teva’s Orange-Book and process patents.
Other programs
• Mid 2011: IND filing for M402, MNTA’s proprietary heparin-based cancer drug, followed by the start of a phase-1 trial.
• Timing and occurrence uncertain: M118 partnership. (Phase-2b/3 trials in ACS are sufficiently large and expensive that MNTA will not conduct such trials without a partner.)
Market Data 
Markets 
AI
